Bone Biologics (BBLG) Income from Continuing Operations (2010 - 2025)
Bone Biologics (BBLG) reported Income from Continuing Operations of 685141.0 for Q4 2025, up 55.36% year-over-year from 441013.75 in Q4 2024, and down 2.57% quarter-over-quarter from 667949.0 in Q3 2025.
Bone Biologics (BBLG) Income from Continuing Operations (2010 - 2025) Analysis & Trends
Bone Biologics (BBLG) has 16 years of Income from Continuing Operations data on file, last reported at 685141.0 in Q4 2025.
- Income from Continuing Operations for Q4 2025 came in at 685141.0, up 55.36% year-over-year; the trailing twelve-month figure through Dec 2025 was 3112958.0 (up 25.23% YoY), and the FY2025 annual result was 3112958.0, up 25.23% from the prior year.
- Income from Continuing Operations retreated to 685141.0 in Q4 2025 per BBLG's latest filing, from 667949.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 176137.0 in Q4 2021 and troughed at 3147537.0 in Q1 2023.
- A 5-year average of 1097311.5 and a median of 848899.5 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations slumped 630.73% in 2022, then soared 73.86% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 176137.0 in 2021, then tumbled by 630.73% to 1287093.0 in 2022, then gained by 9.9% to 1159659.0 in 2023, then slumped by 32.34% to 1534674.0 in 2024, then surged by 55.36% to 685141.0 in 2025.
- Business Quant data shows BBLG's Income from Continuing Operations at 685141.0 in Q4 2025, 667949.0 in Q3 2025, and 741421.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -56.48 Mn |
| 10 | Bone Biologics | 1.47 Mn | 1.47 Mn | - | -685,141.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -685,141.00 |
| Sep 30, 2025 | -667,949.00 |
| Jun 30, 2025 | -741,421.00 |
| Mar 31, 2025 | -1.02 Mn |
| Dec 31, 2024 | -1.53 Mn |
| Sep 30, 2024 | -931,028.00 |
| Jun 30, 2024 | -794,518.00 |
| Mar 31, 2024 | -903,281.00 |
| Dec 31, 2023 | -1.16 Mn |
| Sep 30, 2023 | -2.08 Mn |
| Jun 30, 2023 | -3.04 Mn |
| Mar 31, 2023 | -3.15 Mn |
| Dec 31, 2022 | -1.29 Mn |
| Sep 30, 2022 | -1.22 Mn |
| Jun 30, 2022 | -437,827.00 |
| Mar 31, 2022 | -689,499.00 |
| Dec 31, 2021 | -176,137.00 |
| Sep 30, 2021 | -509,303.00 |
| Jun 30, 2021 | -491,898.00 |
| Mar 31, 2021 | -431,747.00 |